Skip to main content
. 2015 Apr 19;6(15):13072–13087. doi: 10.18632/oncotarget.3865

Figure 5. Targeting Plk1 rescues ATR-Chk1 activity in the context of Wee1 inhibition.

Figure 5

A, B. Panc1 and U2OS cells were treated with combinations of Wee1i, gemcitabine, and the Plk1 inhibitor, GSK 461364 (referred to as Plk1i) at 100nM for 24 h, followed by immunoblot analysis. C, D. Panc1 and U2OS cells were treated with Wee1i, Plk1i, and/or Roscovitine, in the presence of gemcitabine at the indicated concentrations for 8 h. Immunoblots were stained for phosphorylation of Plk1 (Thr210), an indicator of Plk1 activity.